Tretinoin.

Retinol is oxidised to retinaldehyde and then irreversibly to all-trans retinoic acid, which is tretinoin itself. Using both stacks input to the same nuclear receptors.

Retinaldehyde sits one enzymatic step from retinoic acid, converted by retinaldehyde dehydrogenase. It feeds the same receptor pool tretinoin occupies directly.

Retinyl esters are the storage form, hydrolysed to retinol and then oxidised toward retinoic acid. They add to total retinoid signalling load.

Beta-carotene is cleaved centrally by BCO1 into two retinaldehyde molecules, feeding the same retinoid pool. Conversion is regulated, so the contribution is modest but real.

Preformed vitamin A adds directly to retinoid receptor signalling already driven by tretinoin. Total intake matters because retinoid effects stack rather than run in parallel.

Zinc is required for retinol-binding protein synthesis in the liver and for the alcohol dehydrogenase step that oxidises retinol. Retinoid turnover depends on adequate zinc status.

The vitamin D receptor and the retinoic acid receptors both form heterodimers with RXR to bind DNA. The two signals share a limiting partner protein.

Niacinamide supports ceramide synthesis and barrier lipid production, which offsets the barrier disruption that accompanies retinoid use. Standard practice in retinoid regimens.

Retinoid-driven turnover raises transepidermal water loss, and hyaluronic acid holds water in the upper layers. The pairing is about tolerability rather than a shared mechanism.

The conjugated polyene chain of retinoic acid degrades under oxygen and light, and tocopherol is used in formulation to slow that oxidation.

Bakuchiol is not a retinoid but shifts a similar set of collagen and turnover genes. Using both raises the same signalling output with less barrier strain than doubling retinoid dose.

Azelaic acid acts on keratinocyte differentiation at the follicular opening, while tretinoin acts through nuclear retinoid receptors. Two different mechanisms toward the same turnover endpoint.

Both accelerate desquamation, salicylic acid by loosening corneocyte adhesion and tretinoin by driving turnover. Applied together the barrier effects add, so they are usually alternated.

Glycolic acid dissolves corneodesmosome bonds in the stratum corneum while tretinoin thins it from below. Concurrent use compounds irritation rather than adding benefit.

Free ascorbic acid needs a low pH to stay stable while retinoic acid degrades and irritates more under those conditions. The two are usually split between morning and evening.

Ceramides are structural lipids of the stratum corneum and are routinely formulated alongside topical retinoids because retinoid use increases desquamation and transepidermal water loss in the first weeks. The pairing addresses barrier feel and dryness rather than adding to retinoid receptor activity. It is a formulation convention supported by barrier physiology, not by a head to head combination trial.

Squalane is a saturated, oxidation-resistant hydrocarbon emollient that occupies the lipid phase of a cream and reduces the dry, tight feel that accompanies retinoid use. Because it is chemically inert toward the retinoid, it functions as a vehicle component rather than a second active. The trade-off is that a heavier lipid phase changes how much of the applied dose stays at the surface.

Tretinoin is a lipophilic acid with poor water solubility, so it has to be carried in a lipid or surfactant phase. Phospholipids from lecithin act as emulsifiers and liposome formers that keep the molecule dispersed in a stable cream or gel. This is vehicle chemistry, and it says nothing about how much reaches the target cells.

Retinoic acid is readily oxidised and degraded by light and air, and polyphenol antioxidants are commonly included in retinoid formulations to slow that degradation in the pack. Any effect on the skin itself is separate from the stabilisation role and is not established for this pairing. Read it as formulation chemistry rather than a clinical combination.

Astaxanthin is a xanthophyll carotenoid that quenches singlet oxygen in lipid phases, the same phase a retinoid occupies. The rationale for pairing is antioxidant coverage of a photo-exposed lipid environment. No combination study grounds this, so it stays at the lowest confidence band.

Pine bark procyanidins are water-phase antioxidants, complementary to the lipid-phase position a retinoid occupies in a formulation. The pairing is a formulation rationale rather than a demonstrated combined effect. Confidence is held at the lowest band for that reason.

Grape seed procyanidins behave similarly to other polyphenol antioxidants used to protect oxidation-sensitive actives in a finished cream. The interest is stabilisation of the pack and coverage of the aqueous phase. Nothing in the candidate set tests the two together.

Dietary long-chain omega-3 fatty acids are incorporated into epidermal membrane phospholipids and into the lipid lamellae of the stratum corneum. That is why oral omega-3 is sometimes taken during a period of topical retinoid use aimed at barrier comfort. The connection is compositional and indirect, and no combination study is cited here.

Hypericin from St John's wort is a well-characterised photosensitiser, and topical retinoid use already increases skin sensitivity to sunlight through thinning of the stratum corneum. Taken together the two push in the same direction on sun sensitivity, which is worth flagging as an additive effect rather than a benefit. Anyone combining them has more reason, not less, to keep sun exposure controlled.